These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Hormonal therapy with estradiol and testosterone implants: bone protection? Britto R; Araújo L; Barbosa I; Silva L; Rocha S; Valente AP Gynecol Endocrinol; 2011 Feb; 27(2):96-100. PubMed ID: 20504104 [TBL] [Abstract][Full Text] [Related]
3. Increase in bone mass after one year of percutaneous oestradiol and testosterone implants in post-menopausal women who have previously received long-term oral oestrogens. Savvas M; Studd JW; Norman S; Leather AT; Garnett TJ; Fogelman I Br J Obstet Gynaecol; 1992 Sep; 99(9):757-60. PubMed ID: 1420016 [TBL] [Abstract][Full Text] [Related]
4. Improvement of the lipid profile in post menopausal women who use estradiol and testosterone implants. Britto R; Araújo L; Barbosa I; Silva L Gynecol Endocrinol; 2012 Oct; 28(10):767-9. PubMed ID: 22397585 [TBL] [Abstract][Full Text] [Related]
5. 25 mg oestradiol implants--the dosage of first choice for subcutaneous oestrogen replacement therapy? Owen EJ; Siddle NC; McGarrigle HT; Pugh MA Br J Obstet Gynaecol; 1992 Aug; 99(8):671-5. PubMed ID: 1327094 [TBL] [Abstract][Full Text] [Related]
7. Effects of subdermal implants of estradiol and testosterone on the endometrium of postmenopausal women. Filho AM; Barbosa IC; Maia H; Genes CC; Coutinho EM Gynecol Endocrinol; 2007 Sep; 23(9):511-7. PubMed ID: 17943546 [TBL] [Abstract][Full Text] [Related]
8. The relationship between plasma estradiol and the increase in bone density in postmenopausal women after treatment with subcutaneous hormone implants. Studd J; Savvas M; Waston N; Garnett T; Fogelman I; Cooper D Am J Obstet Gynecol; 1990 Nov; 163(5 Pt 1):1474-9. PubMed ID: 2240090 [TBL] [Abstract][Full Text] [Related]
9. The effects of plasma estradiol levels on increases in vertebral and femoral bone density following therapy with estradiol and estradiol with testosterone implants. Garnett T; Studd J; Watson N; Savvas M; Leather A Obstet Gynecol; 1992 Jun; 79(6):968-72. PubMed ID: 1579324 [TBL] [Abstract][Full Text] [Related]
11. Clinical audit of estradiol implant therapy: Long duration of action and implications in non-hysterectomised women. Wheatley S; Bell RJ; Stuckey BG; Robinson PJ; Davis SR Maturitas; 2016 Dec; 94():84-86. PubMed ID: 27823750 [TBL] [Abstract][Full Text] [Related]
12. The effects of subcutaneous hormone implants during climacteric. Cardozo L; Gibb DM; Tuck SM; Thom MH; Studd JW; Cooper DJ Maturitas; 1984 Mar; 5(3):177-84. PubMed ID: 6727691 [TBL] [Abstract][Full Text] [Related]
13. 25 mg oestradiol implants--the dosage of first choice for subcutaneous oestrogen replacement therapy. Bewley S; Bewley T Br J Obstet Gynaecol; 1993 Apr; 100(4):397. PubMed ID: 8494847 [No Abstract] [Full Text] [Related]
14. Subcutaneous hormone implants for the control of climacteric symptoms. A prospective study. Brincat M; Magos A; Studd JW; Cardozo LD; O'Dowd T; Wardle PJ; Cooper D Lancet; 1984 Jan; 1(8367):16-8. PubMed ID: 6140343 [TBL] [Abstract][Full Text] [Related]
15. [Subdermal implantation of estradiol 17 beta (25 mg) in hysterectomized and ovariectomized women. Effects of increased serum estradiol level and neurovegetative climacteric complaints]. Tsvetkov Ts; Tsvetkov K; Petkova U Akush Ginekol (Sofiia); 2001; 41 Suppl 4():11-2. PubMed ID: 11519312 [No Abstract] [Full Text] [Related]
16. Influence of hormone application by subcutaneous injections or steroid-containing silastic implants on human benign hyperplastic prostate tissue transplanted into male nude mice. Claus S; Aumüller G; Tunn S; Senge T; Schulze H Prostate; 1993; 22(3):199-215. PubMed ID: 7683815 [TBL] [Abstract][Full Text] [Related]
17. Effect of combined implants of oestradiol and testosterone on libido in postmenopausal women. Appleby L; Montgomery J Br Med J (Clin Res Ed); 1987 May; 294(6584):1417-8. PubMed ID: 3109683 [No Abstract] [Full Text] [Related]